Companies › HCW Biologics
HCW Biologics: clinical trials, targets and expected readouts
1 active drug program in 1 registered trial: 1 Phase 1; Immunology; next expected readout Jul 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
Programs Drug Target Highest phase Conditions Next expected readout HCW9302 IL-2 fusion protein
IL2 Phase 1 Alopecia Areata(AA) Jul 2027
Trials Registry id Drug Phase Conditions Area Expected readout NCT07049328 HCW9302 Phase 1 Alopecia Areata(AA) Immunology Jul 2027
From the company's SEC filings Cash and short-term investments of $1m on 2026-06-30; operating cash outflow about $11m a year; runway about 1 months at that burn, to Jul 2026
Press releases filed as 8-K in the last year:
Private offerings reported to the SEC (Form D) Agreements filed with the SEC (item 1.01), last two years 2026-09-08 · supply or manufacturing with Akron Biotech · Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent 2026-03-17 · licence · HCW Biologics Closes Exclusive Worldwide License for 2026-02-13 · licence with WY Biotech · HCW Biologics and WY Biotech 2025-11-19 · licence with Beijing Trimmune Biotech · On November 17, 2025, HCW Biologics Inc. (the “Company”) and Beijing Trimmune Biotech Co., Ltd. (“Trimmune”) e 2025-09-05 · licence with WY Biotech · As previously reported on Form 8-K filed on July 18, 2025, HCW Biologics Inc. (the “Company”) and WY Biotech C 2025-08-15 · agreement with Square Gate Capital Master Fund, LLC · As previously reported on February 21, 2025, HCW Biologics Inc. (the “Company,”, “we,” “us,” or “our”) and Squ
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.
Built from ClinicalTrials.gov, CTIS, FDA, PubMed and OpenAlex, read every week; this page from the landscape of 2026-11-09. Phaseline reads registries; it is not investment or medical advice. Method and sources · Privacy · Contact